June 1, 2022
Public Health Ontario has developed interim guidance on the use of the smallpox vaccine Imvamune as post-exposure prophylaxis (PEP) against Monkeypox (attached). Of note, clinical trials of Imvamune have included people living with HIV with a CD4 count of greater than 100. For people with more severe immunosuppression, an additional risk/benefit discussion is indicated before using the vaccine as post-exposure prophylaxis. The guidelines outline when it may be appropriate to use Imvamune as a Monkeypox PEP. You can review this doc here.
The Gay Men’s Sexual Health Alliance (GMSH) is maintaining a webpage where current information is available, in plain language, on ‘what we know’: https://gmsh.ca/monkeypox/
The Toronto Public Health webpage on Monkeypox includes information on symptoms, treatment and prevention, as well as current case counts in Toronto: https://www.toronto.ca/community-people/health-wellness-care/health-programs-advice/monkeypox/
Public Health Ontario has a webpage where information and guidance is available to support the public health response (https://www.publichealthontario.ca/en/Diseases-and-Conditions/Infectious-Diseases/Vector-Borne-Zoonotic-Diseases/Monkeypox).